Jae Jin An, Ph.D. Michael B. Nichol, Ph.D.
|
|
- Morris Parsons
- 6 years ago
- Views:
Transcription
1 IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDOGENEITY BIAS Jae Jin An, Ph.D. Michael B. Nichol, Ph.D. Clinical Pharmacy and Pharmaceutical Economics & Policy Department of Pharmacy University of Southern California ISPOR 16 th Annual International Meeting
2 Outline Background Objective Methods Data Study Population Statistical Methods Results Conclusions Limitations 2
3 Background Diabetes (DM) is an extremely common and costly chronic disease, affecting nearly 8% of the total population in the U.S. Besides the diabetes related complications, 75% of adults had hypertension (HTN) (American Diabetes Association, 2007). Patients with both DM and HTN conditions are required to use multiple medications. The presence of the two diseases and their treatments are associated with a significantly increased risk of cardiovascular mortality and morbidity. 3
4 Background The impact of medication compliance on health outcomes can be investigated using retrospective claims data. However, parameter estimates are likely to be biased in the presence of potential endogeneity. Severe patients would be more compliant with their medications, and then the impact of compliance may be underestimated. Health service seeking patients would be more compliant with their medications, and then the impact of compliance may be overestimated. Endogeneity bias can be controlled using instrumental variables. 4
5 Objective To investigate the impact of multiple medication compliance on the occurrence of cardiovascular complications using instrumental variables (IV) to control for endogeneity bias. 5
6 Methods: Data Source Administrative Claims Data from a Large Physician Group in Southern California Eligibility and Enrollment History Medical Service Claims Pharmacy Claims Electronic Medical Records Clinical Lab Test Values 6
7 Methods: Study Population Inclusion Criteria Index date: First prescription date of either DM or HTN meds during 7/1/2006 6/30/2007 Pre-index period (6 months) Post-index period (33 months) Group 1 (New DM) Group 2 (New HTN) Group 3 (New DM and HTN) Pre-existing Hypertension (Pharmacy Claim) New Diabetes (Pharmacy Claim) New Hypertension Pre-existing Diabetes New Hypertension New Diabetes 7
8 Methods: Study Population Inclusion Criteria 18 years of age or older Continuous eligibility during the study period At least two prescription fills during the post-index period Exclusion Criteria Insulin or inhaler users at baseline and/or post-index period Presence of cardiovascular complications during the preindex period 8
9 Methods: Study Variables Dependent Variable (Binary) Occurrence of major cardiovascular complications using ICD- 9 and CPT codes (=1) Multiple Medication Compliance (Continuous) Proportional Days Covered (PDC) for both simultaneously available oral DM and HTN medications for 33 months of post-index period Covariates Patient demographics: age, gender, health plan, pre-existing condition Severity related factors: number of DM and HTN medications, clinical measures (HbA1C, Blood Pressure, Lipid level), Elixhauser comorbidity 9
10 Methods: Statistical Analyses Descriptive Statistics T-test and Chi-square Tests Probit Model Controlling for observable characteristics Instrumental Variables (IV) - Probit Model Controlling for both observable and unobservable characteristics applying IVs which satisfies relevancy and exogeneity conditions 10
11 Methods: Instrumental Variables Physician related instrumental variables were constructed assuming that patients select their physicians independently of their practice pattern and a physician's practice pattern is unrelated to their use of other medical interventions that might directly influence the outcome. Relevancy and Exogeneity Tests First Stage F statistics (Stock-Yogo table) Shea s R square (p<0.05) Hansen J statistics overidentification test (p>0.05) Wald test of exogeneity (p<0.05) Durbin-Wu-Hausman test (p<0.05) 11
12 Methods: Instrumental Variables IV1: The proportion of follow-up visit per index physician (j) IV2: The proportion of statin prescription during 6 months preindex and 3 months of post-index period per index physician (j) IV3: Dummy for the same prescribers for both disease medications at baseline 12
13 Results: Baseline Characteristics Variables (mean, sd) New DM (N=1,246) New HTN (N=727) New DM and HTN (N=378) Total (N=2,351) Age 63.7 (0.4) 58.7 (0.5) 57.5 (0.7) 61.2 (0.3) Male (%) 45.3% 52.1% 55.9% 49.1% Health care plan (%) Commercial 45.9% 56.0% 58.7% 51.1% Medicare 46.9% 35.5% 34.4% 41.3% Health severity during pre-index Number of Elixhauser comorbidity 1.6 (0.03) 1.5 (0.04) 1.3 (0.05) 1.50 (0.02) HbA1C controlled (%) 41.3% 39.5% 33.6% 39.5% Blood pressure controlled (%) 12.1% 11.3% 6.6% 11.0% Low Density Lipoprotein controlled (%) 29.2% 30.0% 23.3% 28.5% High Density Lipoprotein controlled (%) 37.2% 39.2% 29.6% 36.6% Triglyceride controlled (%) 33.9% 36.7% 32.5% 34.6% Healthcare utilization during pre-index Pharmacy cost ($) 680 (1031) 547 (1050) 124 (673) 550 (1007) Outpatient cost ($) 42 (107) 33 (70) 21 (52) 36 (90) Hospital length of stay 0.2 (0.9) 0.1 (0.7) 0.2 (0.1) 0.2 (0.9) Clinical outcomes during post-index Cardiovascular complication rate (%) 26.4% 23.7% 25.4% 25.4% First cardiovascular complication date 475 (306) 472 (324) 412 (350) 464 (319) 13
14 Results: Medication Compliance Mean Proportion of Days Covered for the 33 Months Post Index Period Patients were more compliant with their pre-existing condition s medications when they had both diabetes and hypertension (p<0.001). When both medications were taken at the same time, the differences in compliance between the two conditions were not significant (p<0.001)
15 Results: Medication Compliance Quarterly Medication Compliance by Group New DM (N=1,246) New HTN (N=727) New DM and HTN (N=378) Compliance with newly started medications dropped significantly in the first quarter (p<0.001) and compliance levels were maintained
16 Results: Probit vs IV-Probit Dependent Variable: Occurrence of cardiovascular complications Models Covariates Compliance Coefficient Standard error p-value Probit None Age Age, gender, health plan, preexisting conditions Severity (clinical measure) IV-Probit +Severity (clinical measure) <0.001 After controlling for observable characteristics, the impact of compliance was statistically insignificant (-0.001±0.10, p=0.990). However, after controlling for both observable and unobservable characteristics, compliance was associated with a significant reduction of cardiovascular complication rates (-1.90±0.53, p<0.001). 16
17 Results: Different Sets of IVs IV Compliance First stage Shea R Durbin-Wu- Hansen J Wald test Coeff. SE F-statisticǂ squareǂ Hausmanǂ statisticǂ exogeneity IV1-2.84*** ** ** IV IV3-2.18*** ** ** IV1, IV2-2.22*** ** * IV1, IV3-2.41*** *** *** IV2, IV3-1.90*** ** ** IV1, IV2, IV3-2.10*** ** ** * p-value <0.05, ** p-value <0.01, *** p-value <0.001, ǂ Statistics were from linear model, SE=Standard error. The results were robust by choosing any combination of three IVs. Final model included IV2 and IV3 as IV1 was redundant. IVs were satisfied identification test criteria. 17
18 Results: Probability of Outcome Compliance Probability of Cardiovascular Complications At Mean Covariates 50% 0.31*** (0.03) 60% 0.26*** (0.01) 70% 0.21*** (0.01) 80% 0.17*** (0.02) 90% 0.13*** (0.02) 100% 0.10** (0.03) ** p-value <0.01, *** p-value <0.001, ( ) are standard errors. Multiple medication compliance was associated with the reduction of probability of cardiovascular complications. The probability of cardiovascular complications was reduced from 0.31 (±0.03) to 0.17 (±0.02) as compliance increased from 50% to 80%
19 Conclusions Compliance with medications for DM and HTN differed when the patient had both conditions at the same time, and patients were more compliant with medications for their pre-existing condition. After controlling for observable and unobservable characteristics, medication compliance was associated with the reduction of cardiovascular complication rates. The magnitude of the compliance impact was greater after controlling for unobservables, which implies that without controlling for endogeneity, the compliance effect would be underestimated. 19
20 Limitations Medication Compliance Compliance with medications were only considered at each disease level, and composite measure of multiple medication compliance was investigated. Medication specific effects, polypharmacy issues within the disease, and compliance with other comorbid conditions have not considered. Instrumental Variables Estimates are unbiased only using valid instruments. Generalizability Study population is only from one physician group in southern California. 20
Hae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.
Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with
More informationCitation for published version (APA): Ebbes, P. (2004). Latent instrumental variables: a new approach to solve for endogeneity s.n.
University of Groningen Latent instrumental variables Ebbes, P. IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationWrite your identification number on each paper and cover sheet (the number stated in the upper right hand corner on your exam cover).
STOCKHOLM UNIVERSITY Department of Economics Course name: Empirical methods 2 Course code: EC2402 Examiner: Per Pettersson-Lidbom Number of credits: 7,5 credits Date of exam: Sunday 21 February 2010 Examination
More informationCLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population
Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Jennifer S. Schultz, PhD; John C. O Donnell, PhD; Ken L. McDonough, MD;
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationAdherence to asthma controller medication regimens
Respiratory Medicine (2005) 99, 1263 1267 Adherence to asthma controller medication regimens D.A. Stempel a,, S.W. Stoloff b, J.R. Carranza Rosenzweig c, R.H. Stanford c, K.L. Ryskina d, A.P. Legorreta
More informationPolicy Brief RH_No. 06/ May 2013
Policy Brief RH_No. 06/ May 2013 The Consequences of Fertility for Child Health in Kenya: Endogeneity, Heterogeneity and the Control Function Approach. By Jane Kabubo Mariara Domisiano Mwabu Godfrey Ndeng
More informationResults of the liberalisation of Medisave for a population-based diabetes management programme in Singapore
Results of the liberalisation of Medisave for a population-based diabetes management programme in Singapore Woan Shin TAN 1, Yew Yoong DING 1, 2, Christine WU 3, Bee Hoon HENG 1 1 Health Services and Outcomes
More informationPCMH 2018 Enrollment and Update August 25, 2017
PCMH 2018 Enrollment and Update August 25, 2017 Enrollment Requirements Anne Santifer HealthCare Innovations Department of Human Services 2018 Enrollment Requirements A physician practice that is enrolled
More informationSupplementary Online Content
Supplementary Online Content Song Z, Ayanian JZ, Wallace J, He Y, Gibson TB, Chernew ME. Unintended consequences of eliminating Medicare payments for consultations. JAMA Intern Med. Published online November
More informationWhat to Expect Today. Example Study: Statin Letter Intervention. ! Review biostatistic principles. ! Hands on application
ASPIRE Workshop 5: Application of Biostatistics Karen Smith, PhD, MS, RPh Thomas Delate, PhD, MS Associate Professor /Clinical Pharmacist Clinical Pharmacy Research Scientist Regis University School of
More informationTools for Targeting High Risk Patients in Your Practice. Statement of Disclosure
Tools for Targeting High Risk Patients in Your Practice Joseph Vande Griend, PharmD, BCPS, CGP Assistant Professor, University of Colorado Departments of Clinical Pharmacy and Family Medicine Skaggs School
More informationPredictive Models for Making Patient Screening Decisions
Predictive Models for Making Patient Screening Decisions MICHAEL HAHSLER 1, VISHAL AHUJA 1, MICHAEL BOWEN 2, AND FARZAD KAMALZADEH 1 1 Southern Methodist University, 2 UT Southwestern Medical Center and
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEffectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
More informationMethods for Addressing Selection Bias in Observational Studies
Methods for Addressing Selection Bias in Observational Studies Susan L. Ettner, Ph.D. Professor Division of General Internal Medicine and Health Services Research, UCLA What is Selection Bias? In the regression
More informationThe chronic nature of schizophrenia is a major contributor
At a Glance Practical Implications p108 Author Information p 115 Full text and PDF www.ajpblive.com Schizophrenia Costs for Newly Diagnosed Versus Previously Diagnosed Patients Treatment Costs Leslie S.
More informationUnderstanding Your Patient Care Opportunity Report (PCOR)
Understanding Your Patient Care Opportunity Report (PCOR) Use your January/February 208 PCOR to help improve performance on Medicare Part D Clinical Star Ratings measures. Your January/February 208 Patient
More informationHedis Behavioral Health Measures
Hedis Behavioral Health Measures Generating better health outcomes and improving HEDIS scores is a positive outcome for everyone. Magellan Complete Care is offering support by providing the details of
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationMedicaid provides prescription drugs for certain
At a Glance Impact of Medicaid Preferred Drug List on Long-Acting Opioid Users Practical Implications p 210 Author Information p 215 Full text and PDF www.ajpblive.com Natalie R. Jacuzzi, MPH; K. John
More informationApurba Chakraborty MBBS, MPH Dima M. Qato PharmD, MPH, PhD Professor Mark S. Dworkin MD, MPHTM The University of Illinois at Chicago
Less is More: The Impact of Lower Pill Burden on Adherence to Antiretroviral Therapy among Treatment-Naive Patients with HIV Infection in the United States Apurba Chakraborty MBBS, MPH Dima M. Qato PharmD,
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationThe Impact of Relative Standards on the Propensity to Disclose. Alessandro Acquisti, Leslie K. John, George Loewenstein WEB APPENDIX
The Impact of Relative Standards on the Propensity to Disclose Alessandro Acquisti, Leslie K. John, George Loewenstein WEB APPENDIX 2 Web Appendix A: Panel data estimation approach As noted in the main
More informationDoes Machine Learning. In a Learning Health System?
Does Machine Learning Have a Place In a Learning Health System? Grand Rounds: Rethinking Clinical Research Friday, December 15, 2017 Michael J. Pencina, PhD Professor of Biostatistics and Bioinformatics,
More informationISPOR Good Research Practices for Retrospective Database Analysis Task Force
ISPOR Good Research Practices for Retrospective Database Analysis Task Force II. GOOD RESEARCH PRACTICES FOR COMPARATIVE EFFECTIVENESS RESEARCH: APPROACHES TO MITIGATE BIAS AND CONFOUNDING IN THE DESIGN
More informationImproved IPGM: Demonstrating the Value to both Patients and Hospitals
Improved IPGM: Demonstrating the Value to both Patients and Hospitals Osama Hamdy, MD, PhD, FACE Medical Director, Inpatient Diabetes Program Joslin Diabetes Center Harvard Medical School, Boston, MA Cost
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationHEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES
HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES Presented by Parul Agarwal, PhD MPH 1,2 Thomas K Bias, PhD 3 Usha Sambamoorthi,
More informationIsolating causality between gender and corruption: An IV approach Correa-Martínez, Wendy; Jetter, Michael
No. 16-07 2016 Isolating causality between gender and corruption: An IV approach Correa-Martínez, Wendy; Jetter, Michael Isolating causality between gender and corruption: An IV approach 1 Wendy Correa
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationCost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease
Volume 12 Number 2 2009 VALUE IN HEALTH Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease Joel W. Hay, PhD, 1 Elizabeth Lawler, ScD, MPH, 2,3 Kent Yucel, MD, MPH,
More informationA. Sicras-Mainar 1*, L. Sánchez-Álvarez 2, R. Navarro-Artieda 3 and J. Darbà 4
Sicras-Mainar et al. Lipids in Health and Disease (2018) 17:277 https://doi.org/10.1186/s12944-018-0918-y RESEARCH Treatment persistence and adherence and their consequences on patient outcomes of generic
More informationAuthors: Shuling Li, PhD 1, Julia Molony, MS 1, Karynsa Cetin, MPH 2, Jeffrey Wasser, MD 3, Ivy Altomare, MD 4
Rate of Bleeding-Related Episodes (BREs) in Elderly Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study Using Medicare 20% Sample Data Authors: Shuling Li,
More informationStudy Exposures, Outcomes:
GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic
More informationThe Effects of Maternal Alcohol Use and Smoking on Children s Mental Health: Evidence from the National Longitudinal Survey of Children and Youth
1 The Effects of Maternal Alcohol Use and Smoking on Children s Mental Health: Evidence from the National Longitudinal Survey of Children and Youth Madeleine Benjamin, MA Policy Research, Economics and
More informationTable 2. Distribution of Normalized Inverse Probability of Treatment Weights. Healthcare costs (US $2012) Notes:
228 COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND MEDICAID SPENDING AMONG PATIENTS WITH SCHIZOPHRENIA TREATED WITH ONCE MONTHLY PALIPERIDONE PALMITATE OR ORAL ATYPICAL ANTIPSYCHOTICS USING THE INVERSE
More informationReal World Patients: The Intersection of Real World Evidence and Episode of Care Analytics
PharmaSUG 2018 - Paper RW-05 Real World Patients: The Intersection of Real World Evidence and Episode of Care Analytics David Olaleye and Youngjin Park, SAS Institute Inc. ABSTRACT SAS Institute recently
More informationImpact of Eliminating Medicaid Adult Dental Coverage in California on Emergency. Department Use for Dental Problems
Impact of Eliminating Medicaid Adult Dental Coverage in California on Emergency Department Use for Dental Problems Introduction: Oral health is an integral part of overall well-being. Apart from having
More informationTechnical Track Session IV Instrumental Variables
Impact Evaluation Technical Track Session IV Instrumental Variables Christel Vermeersch Beijing, China, 2009 Human Development Human Network Development Network Middle East and North Africa Region World
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sutton M, Nikolova S, Boaden R, Lester H, McDonald R, Roland
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationDetecting Anomalous Patterns of Care Using Health Insurance Claims
Partially funded by National Science Foundation grants IIS-0916345, IIS-0911032, and IIS-0953330, and funding from Disruptive Health Technology Institute. We are also grateful to Highmark Health for providing
More informationThe Impact of Proton Pump Inhibitor Compliance on Health-Care Resource Utilization and Costs in Patients with Gastroesophageal Reflux Disease
Volume 12 Number 1 2009 VALUE IN HEALTH The Impact of Proton Pump Inhibitor Compliance on Health-Care Resource Utilization and Costs in Patients with Gastroesophageal Reflux Disease Antoine Gosselin, MA,
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationUpdate in Outpatient Medicine ACP Scientific Session November 12, 2016
Update in Outpatient Medicine ACP Scientific Session November 12, 2016 Robert Gluckman MD, MACP Chief Medical Officer Providence Health Plans Disclosures Stock Holdings Abbott Labs Abbvie Bristol Myers
More informationThe US Food and Drug Administration (FDA) requires that
Prescriber Compliance With Black Box Warnings in Older Adult Patients Judith A. Ricci, ScD, MS; Charmaine Coulen, MPH; Jan E. Berger, MD, MJ; Marsha C. Moore, MD, MBA; Angela McQueen, PharmD; and Saira
More informationSocial contagion in new product trial and repeat
Social contagion in new product trial and repeat Raghuram Iyengar, Christophe Van den Bulte, Jae Young Lee The Wharton School University of Pennsylvania 2014 ECMI-AMA-EMAC Marketing & Innovation Symposium
More informationMail Service Pharmacy
Mail Service s At A Glance Disclaimer: reserves the right to update its measures and measure sets to maintain measure relevancy and to remedy any unintended consequences that may arise during implementation.
More informationCARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS. Mugdha Gokhale.
CARDIOVASCULAR EFFECTS OF INCRETIN-BASED ANTIHYPERGLYCEMIC DRUGS RELATIVE TO TREATMENT ALTERNATIVES IN OLDER ADULTS Mugdha Gokhale A dissertation submitted to the faculty at the University of North Carolina
More informationMeasure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner
2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current
More informationIncreasing Patient Activation to Improve Health and Reduce Costs
Increasing Patient Activation to Improve Health and Reduce Costs Judith H. Hibbard, DrPH Institute for Policy Research and Innovation University of Oregon 2008 University of Oregon There is great variation
More informationArkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual
Arkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual 2017 This document is a guide to the 2017 Arkansas Blue Cross and Blue Shield Patient-Centered Medical
More informationClinical Quality Measures Summary of Upcoming Enhancements
Upcoming coding enhancements will impact the logic behind the clinical quality indicators applicable to your practice specialty. Please refer to this grid for a summary of the coding enhancements and some
More informationLeveraging Data for Targeted Patient Population Health Improvements
Leveraging Data for Targeted Patient Population Health Improvements Diabetes Impact on Health in America Diabetes is a major health concern in the United States today. The Centers for Disease Control
More informationoutcome measures were adherence, medication possession ratio (MPR), persistence, prescription count, and duration of therapy.
ORIGINAL RESEARCH Patient Adherence with HMG Reductase Inhibitor Therapy among Users of Two Types of Prescription Services by T. Jeffrey White, Pharm.D., M.S., Eunice Chang, Ph.D., Scott Leslie, M.P.H.,
More informationComparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast
RESPIRATORY MEDICINE (2001) 95, 227 234 doi:10.1053/rmed.2000.1027, available online at http://www.idealibrary.com on Comparison of asthma costs in patients starting fluticasone propionate compared to
More informationMedicare Advantage Measurement Period Handbook for Enhanced Personal Health Care Measurement Period beginning January 1, 2015
Medicare Advantage Measurement Period Handbook for Enhanced Personal Health Care Measurement Period beginning January 1, 2015 Amerivantage is an HMO plan with a contract with the New Mexico Medicare program.
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 218 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationInstrumental Variables I (cont.)
Review Instrumental Variables Observational Studies Cross Sectional Regressions Omitted Variables, Reverse causation Randomized Control Trials Difference in Difference Time invariant omitted variables
More informationInstrumental Variables Estimation: An Introduction
Instrumental Variables Estimation: An Introduction Susan L. Ettner, Ph.D. Professor Division of General Internal Medicine and Health Services Research, UCLA The Problem The Problem Suppose you wish to
More informationEvaluating the Matlab Interventions Using Non-standardOctober Methods10, and2012 Outcomes 1 / 31
Evaluating the Matlab Interventions Using Non-standard Methods and Outcomes Julia Driessen University of Pittsburgh October 10, 2012 Evaluating the Matlab Interventions Using Non-standardOctober Methods10,
More informationKey Quality of Care Measures. Blue Cross Blue Shield of Michigan Traditional, PPO and POS Members. Fourth Quarter 2003
Key Quality of Care Measures Blue Cross Blue Shield of Michigan Traditional, PPO and POS Members Fourth Quarter 2003 Blue Cross Blue Shield of Michigan is a nonprofit corporation and independent licensee
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationAcarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and. Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice
Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice Authors: Chi-Chen Lin, Der-Yuan Chen, Ya-Hsuan Chao,
More informationPredictive Models for Making Patient Screening Decisions
Predictive Models for Making Patient Screening Decisions MICHAEL HAHSLER 1, VISHAL AHUJA 1, MICHAEL BOWEN 2, AND FARZAD KAMALZADEH 1 1 Southern Methodist University, 2 UT Southwestern Medical Center and
More informationPatient adherence to chronic disease medications in a medication therapy management program in Lucas County, Ohio
The University of Toledo The University of Toledo Digital Repository Theses and Dissertations 2009 Patient adherence to chronic disease medications in a medication therapy management program in Lucas County,
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationHow Engaged Are Consumers in Their Health. It Matter? What is Patient Activation or Engagement
2008 University of Oregon How Engaged Are Consumers in Their Health and Health Care, and Why Does It Matter? Judith H. Hibbard, DrPH Institute for Policy Research and Innovation University of Oregon What
More informationPQRS in TRAKnet 2015 GUIDE TO SUBMIT TING AND REPORTING PQRS IN 2015 THROUGH TRAKNET
PQRS in TRAKnet 2015 GUIDE TO SUBMITTING AND REPORTING PQRS IN 2015 THROUGH TRAKNET What is PQRS? PQRS is a quality reporting program that uses negative payment adjustments to promote reporting of quality
More informationDiabetes Quality Improvement Initiative
Diabetes Quality Improvement Initiative Community Care of North Carolina 2300 Rexwoods Drive, Ste. 100 Raleigh, NC 27607 (919) 745-2350 www.communitycarenc.org 2007 Background The Clinical Directors of
More informationDrug Therapy Management
Measures At A Glance Updated: 11/01/2018 2018 Page 1 of 9 Mandatory Measures (10) Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to on an annual
More informationKEY BEHAVIORAL MEASURES
2019 HEDIS AT-A-GLANCE: KEY BEHAVIORAL MEASURES (17 Years and Younger) At WellCare, we value everything you do to deliver quality care for our members your patients to make sure they have a positive healthcare
More informationImpact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost Medical Care. 2005;43:521-530. Presented by Rodger Kormylo to the ACSW 11/10/2005 Medco is a registered trademark of Medco Health
More informationReport to the Social Services Appropriations Subcommittee
Report to the Social Services Appropriations Subcommittee Medicaid Coverage and Reimbursement for Outpatient Physical Therapy and Outpatient Occupational Therapy Prepared by the Division of Medicaid and
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationPropensity Score Matching with Limited Overlap. Abstract
Propensity Score Matching with Limited Overlap Onur Baser Thomson-Medstat Abstract In this article, we have demostrated the application of two newly proposed estimators which accounts for lack of overlap
More informationEMPIRICAL STRATEGIES IN LABOUR ECONOMICS
EMPIRICAL STRATEGIES IN LABOUR ECONOMICS University of Minho J. Angrist NIPE Summer School June 2009 This course covers core econometric ideas and widely used empirical modeling strategies. The main theoretical
More informationLecture II: Difference in Difference. Causality is difficult to Show from cross
Review Lecture II: Regression Discontinuity and Difference in Difference From Lecture I Causality is difficult to Show from cross sectional observational studies What caused what? X caused Y, Y caused
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationEstimating Medicaid Costs for Cardiovascular Disease: A Claims-based Approach
Estimating Medicaid Costs for Cardiovascular Disease: A Claims-based Approach Presented by Susan G. Haber, Sc.D 1 ; Boyd H. Gilman, Ph.D. 1 1 RTI International Presented at The 133rd Annual Meeting of
More informationStudy Objectives. To understand the influence of socio-economic factors, from a physician viewpoint, regarding the patients :
1 Impact of Socio-Economic Factors on Patients Knowledge of their Condition, Involvement in Treatment Decisions and Subsequent Compliance with their Treatment Regimen ISPOR, Dublin Oct 20-23 2007 M Palm,
More informationTHE ECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN A WORKING AGE AND COMMERCIALLY INSURED POPULATION. Christopher John Wallick
THE ECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN A WORKING AGE AND COMMERCIALLY INSURED POPULATION Christopher John Wallick A thesis submitted in partial fulfillment of the requirements for the degree
More informationPrescription Switching and Reduced LDL-C Goal Attainment
Prescription Switching and Reduced LDL-C Goal Attainment JoAnne M. Foody, MD, FACC, FAHA Brigham and Women's Hospital, Boston, MA Disclosures Consultant for Merck and Pfizer Why Address Adherence? Increasing
More informationHow Doctors Choose Medicines when Treating Patients with Type 2 Diabetes
HARVARD MEDICAL SCHOOL How Doctors Choose Medicines when Treating Patients with Type 2 Diabetes Richard W. Grant MD MPH Endocrine Society Beta Cell meeting January 9-10, 2009 Outline Background Observed
More informationWe see health care. differently. Comprehensive data Novel insights Transformative actions Lasting value
We see health care differently Comprehensive data Novel insights Transformative actions Lasting value 24 Hours of Optum data: Creating a more complete health picture We capture: Largest EHR dataset 90
More informationUnitedHealth Premium Program Case-mix, Severity and Risk
UnitedHealth Premium Program Case-mix, Severity and Risk Resources u Phone: 866-270-5588 u u Website: UnitedHealthPremium.UHC.com Mail: UnitedHealthcare - UnitedHealth Premium Program MN017-W700 9700 Health
More informationRole of Pharmacoepidemiology in Drug Evaluation
Role of Pharmacoepidemiology in Drug Evaluation Martin Wong MD, MPH School of Public Health and Primary Care Faculty of Medicine Chinese University of Hog Kong Outline of Content Introduction: what is
More informationA Retrospective Claims Analysis of Medication Adherence and. Persistence Among Patients Taking Antidepressants
A Retrospective Claims Analysis of Medication Adherence and Persistence Among Patients Taking Antidepressants for the Treatment of Major Depressive Disorder (MDD) Katelyn R. Keyloun A thesis submitted
More informationPBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.
Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences
More informationTHE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE
THE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE Washington University grants permission to use and reproduce the The Importance of Comorbidity
More informationEffects of a home-based aerobic exercise program on glycosylated. hemoglobin and the peak oxygen uptake in children and. adolescents With Type 1 DM
Effects of a home-based aerobic exercise program on glycosylated hemoglobin and the peak oxygen uptake in children and adolescents With Type 1 DM Abstract Aims and objective. To explore the effects of
More information